An FDA advisory committee on Wednesday unanimously voted against recommending approval of the PARP inhibitor talazoparib ...

The results of this phase III KEYNOTE-991 study do not support the addition of pembrolizumab to enzalutamide and ADT for the treatment of mHSPC,” researchers wrote.

As of this writing, the role of PD-L1 inhibitors in prostate cancer remains limited to a subset of patients with metastatic microsatellite instability-high, mismatch repair-deficient, or tumor ...

The combination of enzalutamide with androgen deprivation therapy (ADT) significantly increases the chance of five-year survival for men with metastatic hormone-sensitive prostate cancer, according to ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from an open-label extension of the Phase 3 ...

Discover a study that also highlighted that treatment intensification with enzalutamide benefited patients regardless of ...

VALOR study: A phase II trial of vorinostat to augment response to 177Lutetium-PSMA-617 in the treatment of patients with PSMA-low metastatic castration resistant prostate cancer. This is an ASCO ...

A randomized phase III trial investigating platinum and taxane chemotherapy in metastatic castration resistant prostate cancer (mCRPC) patients with alterations in DNA damage response (DDR) genes ...

Oncology specialists from UC San Francisco will present new clinical research findings and cutting-edge treatment strategies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, ...